Screener
Agios Pharmaceuticals AGIO Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 |
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 |
| Loss from operations | (110,552) | (127,056) | (220,577) | (233,685) |
| Interest income, net | 9,730 | 14,513 | 20,525 | 30,600 |
| Other income, net | 119 | 523 | 238 | 1,776 |
| Net loss | $(100,703) | $(112,020) | $(199,814) | $(201,309) |
| Net loss per share - basic and diluted | $(1.69) | $(1.93) | $(3.38) | $(3.49) |
| Weighted-average number of common shares used in computing net loss per share – basic and diluted | 59,488,871 | 57,932,576 | 59,137,508 | 57,697,193 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's other income, net (note 6)?
- Agios Pharmaceuticals (AGIO) reported other income, net (note 6) of $119K in Q2 2026.
- How has Agios Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Agios Pharmaceuticals's other income, net (note 6) decreased by 77.2% year-over-year, from $523K to $119K.
- What is the long-term trend for Agios Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's other income, net (note 6) has grown at a -39.3% compound annual growth rate (CAGR), from $14.43M to $1.96M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Agios Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude